Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $18.56 Average Target Price from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $18.56.

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. Barclays increased their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $17.11 on Monday. The company has a market cap of $19.37 billion, a price-to-earnings ratio of -41.72, a price-to-earnings-growth ratio of 1.45 and a beta of 0.90. Teva Pharmaceutical Industries has a 12 month low of $8.06 and a 12 month high of $17.69. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.89 and a quick ratio of 0.61. The stock’s 50-day moving average is $16.76 and its 200-day moving average is $14.51.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). The business had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. Equities analysts anticipate that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares in the company, valued at $16,706,430. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Mignone sold 519,000 shares of the stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the sale, the director now owns 981,000 shares in the company, valued at approximately $16,706,430. The disclosure for this sale can be found here. Insiders have sold 549,719 shares of company stock worth $9,353,736 in the last three months. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janney Montgomery Scott LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 13.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock worth $19,366,000 after purchasing an additional 164,614 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Teva Pharmaceutical Industries by 705.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after acquiring an additional 507,568 shares during the period. QRG Capital Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 53.7% during the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after acquiring an additional 50,247 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock worth $5,689,000 after acquiring an additional 131,043 shares during the period. Finally, Wellington Management Group LLP lifted its position in Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after purchasing an additional 102,261 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.